Warner Chilcott reports Q1 earnings

ARDEE, Ireland The growth of three drugs helped push Warner Chilcott’s revenue more than 7% higher for first quarter 2009 than for first quarter 2008, according to financial results released Monday.

The drug maker’s revenues for the quarter were $246 million, a 7.2% increase over last year, helped mostly by sanes of Doryx (ddd), Loestrin 24 FE (ddd) and Estrace Cream (ddd), which together contributed $24.8 million in revenue growth.

The company also reported net income of $43.3 million, compared with $33.7 million last year, a 28.8% increase. Cash net income rose by 17.9%, to $97.7 million.